Merrill keeps Angiotech at buy

Angiotech Pharmaceuticals Inc. was kept at its buy rating by Merrill Lynch analyst Hari Sambasivam. Merrill updated its model, raising its Taxus sales estimates. The analyst's pro forma earnings-per-share estimates for 2006 to 2008 are $0.82, $1.32 and $1.53, compared with the previous estimates of $0.86, $1.26 and $1.44 previously. Shares of the Vancouver, B.C., pharmaceutical company were up 1 cent, or 0.07%, at $14.80 on volume of 291,873 shares versus the three-month running average of 720,571 shares. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.